BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

608 related articles for article (PubMed ID: 28445298)

  • 1. Barcelona clinic liver cancer-stage C hepatocellular carcinoma: A novel approach to subclassification and treatment.
    Jun CH; Yoon JH; Cho E; Shin SS; Cho SB; Kim HJ; Park CH; Kim HS; Choi SK; Rew JS
    Medicine (Baltimore); 2017 Apr; 96(17):e6745. PubMed ID: 28445298
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overall survival in response to sorafenib with transarterial chemoembolization for BCLC stage B hepatocellular carcinoma: propensity score analysis
.
    Huang Y; Chen B; Liu N; Li N; Dao H; Chen W; Yang J
    Int J Clin Pharmacol Ther; 2017 Jun; 55(6):498-508. PubMed ID: 28157070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic Factors for Survival After Transarterial Chemoembolization Combined with Sorafenib in the Treatment of BCLC Stage B and C Hepatocellular Carcinomas.
    Ni JY; Kong J; Sun HL; Chen YT; Luo JH; Wang WD; Chen D; Jiang XY; Xu LF
    Acad Radiol; 2018 Apr; 25(4):423-429. PubMed ID: 29198946
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Different survival of Barcelona clinic liver cancer stage C hepatocellular carcinoma patients by the extent of portal vein invasion and the type of extrahepatic spread.
    Sinn DH; Cho JY; Gwak GY; Paik YH; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC
    PLoS One; 2015; 10(4):e0124434. PubMed ID: 25923439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sorafenib combined with transarterial chemoembolization versus transarterial chemoembolization alone for advanced-stage hepatocellular carcinoma: a propensity score matching study.
    Hu H; Duan Z; Long X; Hertzanu Y; Shi H; Liu S; Yang Z
    PLoS One; 2014; 9(5):e96620. PubMed ID: 24817002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined transarterial chemoembolization and radiotherapy as a first-line treatment for hepatocellular carcinoma with macroscopic vascular invasion: Necessity to subclassify Barcelona Clinic Liver Cancer stage C.
    Kim YJ; Jung J; Joo JH; Kim SY; Kim JH; Lim YS; Lee HC; Kim JH; Yoon SM
    Radiother Oncol; 2019 Dec; 141():95-100. PubMed ID: 31506181
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survival outcomes of hepatic resection compared with transarterial chemoembolization or sorafenib for hepatocellular carcinoma with portal vein tumor thrombosis.
    Lee JM; Jang BK; Lee YJ; Choi WY; Choi SM; Chung WJ; Hwang JS; Kang KJ; Kim YH; Chauhan AK; Park SY; Tak WY; Kweon YO; Kim BS; Lee CH
    Clin Mol Hepatol; 2016 Mar; 22(1):160-7. PubMed ID: 27044767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resubclassification and clinical management for Barcelona Clinic Liver Cancer Stage C hepatocellular carcinoma.
    Lin CW; Chen YS; Lo GH; Wu TC; Yeh JH; Yeh ML; Dai CY; Huang JF; Chuang WL; Roberts L; Jun DW; Toyoda H; Yasuda S; Nguyen MH; Yu ML
    Hepatol Int; 2021 Aug; 15(4):946-956. PubMed ID: 34008091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sub-classification of Advanced-Stage Hepatocellular Carcinoma: A Cohort Study Including 612 Patients Treated with Sorafenib.
    Yoo JJ; Chung GE; Lee JH; Nam JY; Chang Y; Lee JM; Lee DH; Kim HY; Cho EJ; Yu SJ; Kim YJ; Yoon JH;
    Cancer Res Treat; 2018 Apr; 50(2):366-373. PubMed ID: 28521494
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic ability of BCLC-B Subclassification in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization.
    Biolato M; Gallusi G; Iavarone M; Cabibbo G; Racco S; De Santis A; Corte CD; Maida M; Attili AF; Sangiovanni A; Cammà C; La Torre G; Gasbarrini A; Grieco A
    Ann Hepatol; 2018; 17(1):110-118. PubMed ID: 29311396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant sorafenib after heptectomy for Barcelona Clinic Liver Cancer-stage C hepatocellular carcinoma patients.
    Xia F; Wu LL; Lau WY; Huan HB; Wen XD; Ma KS; Li XW; Bie P
    World J Gastroenterol; 2016 Jun; 22(23):5384-92. PubMed ID: 27340354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of Hepatocellular Carcinoma.
    Díaz-González Á; Reig M; Bruix J
    Dig Dis; 2016; 34(5):597-602. PubMed ID: 27332893
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sorafenib with TACE improves the survival of hepatocellular carcinoma patients with more than 10 cm tumor: a single-center retrospective study.
    Aktas G; Kus T; Emin Kalender M; Kervancioglu S; Sevinc A; Kul S; Camci C
    J BUON; 2017; 22(1):150-156. PubMed ID: 28365948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic assessment using a new substaging system for Barcelona clinic liver cancer stage C hepatocellular carcinoma: A nationwide study.
    Lee DW; Yim HJ; Seo YS; Na SK; Kim SY; Suh SJ; Hyun JJ; Jung SW; Jung YK; Koo JS; Kim JH; Yeon JE; Lee SW; Byun KS; Um SH
    Liver Int; 2019 Jun; 39(6):1109-1119. PubMed ID: 30972935
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sorafenib combined with transarterial chemoembolization for the treatment of advanced hepatocellular carcinoma: a large-scale multicenter study of 222 patients.
    Zhao Y; Wang WJ; Guan S; Li HL; Xu RC; Wu JB; Liu JS; Li HP; Bai W; Yin ZX; Fan DM; Zhang ZL; Han GH
    Ann Oncol; 2013 Jul; 24(7):1786-1792. PubMed ID: 23508822
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of survival in patients with established cirrhosis and hepatocellular carcinoma treated with sorafenib.
    Inghilesi AL; Gallori D; Antonuzzo L; Forte P; Tomcikova D; Arena U; Colagrande S; Pradella S; Fani B; Gianni E; Boni L; Laffi G; Di Costanzo F; Marra F
    World J Gastroenterol; 2014 Jan; 20(3):786-94. PubMed ID: 24574751
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Significance of liver resection for intermediate stage hepatocellular carcinoma according to subclassification.
    Yamamoto M; Kobayashi T; Hashimoto M; Kuroda S; Kawaoka T; Aikata H; Chayama K; Ohdan H
    BMC Cancer; 2021 Jun; 21(1):668. PubMed ID: 34090354
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatocellular Carcinoma Management in Nonalcoholic Fatty Liver Disease Patients: Applicability of the BCLC Staging System.
    Kikuchi L; Oliveira CP; Alvares-da-Silva MR; Tani CM; Diniz MA; Stefano JT; Chagas AL; Alencar RS; Vezozzo DC; Santos GR; Campos PB; Alves VA; Ratziu V; Carrilho FJ
    Am J Clin Oncol; 2016 Oct; 39(5):428-32. PubMed ID: 25268068
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of TACE and Sorafenib Improves Outcomes in BCLC Stages B/C of Hepatocellular Carcinoma: A Single Centre Experience.
    Varghese J; Kedarisetty C; Venkataraman J; Srinivasan V; Deepashree T; Uthappa M; Ilankumaran K; Govil S; Reddy M; Rela M
    Ann Hepatol; 2017; 16(2):247-254. PubMed ID: 28233748
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Impact of Combined Transarterial Chemoembolization on the Overall Survival of Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib.
    Chen L; Su H; Shao H; Xu K; Liang S; Liu J
    Hepatogastroenterology; 2014 May; 61(131):802-8. PubMed ID: 26176077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.